Olive Leaf Extracts in the Control of Cardiovascular Risk

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

Also called NCT05297110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05297110
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Tunisia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05297110. Randomized; single masking; primary purpose prevention. Start 2021-08-01 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Olive Leaf Extracts in the Control of Cardiovascular Risk
Acronym
Atherolive
Condition
Diabetes Mellitus, Type 2
Condition
Hypertension
Intervention (Drug)
atherolive
Lead sponsor
University of Monastir (class: other)

Record details

Record id
cardio:ct-nct05297110
Content hash
60ddd36fb8b82c9dab8870c2925bb40169ff93668fff73f608503e0e88c474ff